Clinical trial · Observational
DEB-BACE for Primary Lung Cancer: A Retrospective, Single-Arm, Multicenter Study on Efficacy and Safety
NCT07072299CI-TRIAL-00092334not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a retrospective, single-arm, multicenter clinical study designed to evaluate the efficacy and safety of DEB-BACE (Drug-Eluting Bead Bronchial Artery Chemoembolization) in the treatment of primary lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer Patients | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DEB-BACE | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- ORR
- timeFrame
- up to 1 years
- description
- ORR is defined as the percentages of patients, relative to the total of enrolled subjects, achieving a complete (CR) or partial (PR) response, according to mRECIST 1.1 criteria
Secondary outcomes (2)
- measure
- PFS
- timeFrame
- up to 1 years
- description
- PFS was defined as the time from recruitment to the first documented progressive disease (PD) or death due to any cause, whichever occurred first.
- measure
- OS
- timeFrame
- up to1 years
- description
- The time from recruitment to death due to any cause
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 1\. Age ≥ 18 years old, gender unrestricted; 2. Diagnosed with primary lung cancer based on the Primary Lung Cancer Diagnosis and Treatment Guidelines (2022 Edition) through histopathological examination; 3. At least one measurable lesion (evaluated according to RECIST 1.1 criteria); 4. Previously received at least one DEB-BACE treatment; 5. ECOG PS score ≤ 2; 6. Complete patient case records. Exclusion Criteria: * 1\. Presence of extensive and uncontrolled extrapulmonary brain metastasis lesions; 2. Irreversible coagulation dysfunction within a short period of time; 3. Uncontrollable hypertension, diabetes, or significant cardiovascular diseases with obvious symptoms; 4. Allergy to contrast agent; 5. Pregnant or lactating women; 6. Patients whose condition, as judged by the investigator, poses a serious threat to patient safety or hinders their participation in the study.
References
Publications (0)
Data not yet available
No reference posted for this study.